Tumor stem cells (TSCs) have been identified in many malignant tumors and are unique in their self-renewal, multi-differentiation and tumor growth maintenance capabilities. Micro-RNAs (miRNAs) are small endogenous, non-coding RNAs that predominately modulate target gene expression at the post-transcriptional level. Accumulating evidence suggests that some miRNAs have an essential role in TSC proliferation, growth, apoptosis, and differentiation. In particular, miR-34a has been found to inhibit proliferation and induce apoptosis in stem cells.
Introduction
As a result of its highly malignant bio-behavior, glioma remains one of the most refractory tumors to therapy. Accumulating evidence suggests that many tumors contain a subpopulation of cells that has the ability to self-renew, form neurospheres, generate daughter cells of different phenotypes from a single mother cell, and differentiate into phenotypically diverse populations of cells that are similar to the initial cell. These cells are termed tumor stem cells (TSCs) (1, 2) . Additionally, the subpopulation of cells has also been found in both glioma tissues and glioma cell lines (3) (4) (5) (6) , which, in this setting, are called glioma stem cells (GSCs). GSCs are considered glioma-initiating cells, and are crucial for the malignancy and recurrence of glioma (7, 8) . The GSC model has greatly changed the biological and clinical views of glioma; however, the mechanisms underlying GSC's involvement in tumorigenesis are still unclear.
MicroRNAs (miRNAs) are small non-coding RNAs of 20-25 nucleotides that modulate target gene expression by binding with target mRNA sequences in the 3′ untranslated region (UTR) to inhibit the translation or degradation of mRNA. Abnormally expressed miRNA can act as a tumor oncogene or anti-oncogene in Technology in Cancer Research & Treatment, Volume 11, Number 5, October 2012 many solid tumors (9, 10) . Accumulating evidence suggests that some miRNA have an essential role in TSC proliferation and multi-differentiation (11) (12) (13) . MiR-34a, a direct target of p53 (14-16), acts as a tumor suppressor to inhibit cell growth, induce G0-G1 phase cell cycle arrest, and decrease cellular invasive potential in both p53-mutant U251 cells and p53-wild-type U87 cells (17, 18) , in addition to suppressing cell proliferation and inducing cell apoptosis and differentiation in 0308 and 1228 GSCs (19) . However, the mechanism underlying miR-34a's function in U87 GSCs is still unknown. In the present study, we isolated GSCs from U87 cell cultures and found that the expression level of miR-34a was significantly down-regulated in U87 GSCs in contrast to normal U87 cells, which indicates that miR-34a may have a functional role in U87 GSCs. Furthermore, we analyzed the effects and mechanism of miR-34a action in U87 GSCs. Our results demonstrate that over-expression of miR-34a inhibits cell proliferation and induces apoptosis in GSCs. Additionally, miR-34a modulates the expression levels of proliferation-associated proteins, such as cyclin D1, c-myc, c-met, ki-67, and apoptosis-associated proteins, including Bcl-2, Bcl-xL, Bcl-w, Bax. Our data show that miR-34a acts as a tumor suppressor in U87 GSCs and suggests the potential for a new "drug" for GSC-based glioma treatment.
Materials and Methods

Isolation and Culture of U87 GSCs
The U87 human glioma cell line was purchased from the Chinese Academy of Sciences Cell Bank. U87 cells were maintained in a 37°C, 5% CO 2 incubator in DMEM supplemented with 10% fetal bovine serum (FBS) and were routinely passaged at two or three day intervals. In this study, U87 GSCs were sorted by fluorescence-activated cell sorting (FACS) on a FACSCalibur instrument based on staining with a mouse anti-human CD133 antibody (Miltenyi Biotec). CD133 is a cell surface marker of neural stem cells and has been used for enriching GSCs from glioma samples or cell lines in most relevant studies. GSCs were grown in serum-free neural stem cell medium, specifically, DMEM/ F12 medium (Hyclone, USA) supplemented with B27 (13, Gibco, USA), recombinant human epidermal growth factor (rhEGF, 20 ng/ml; PeproTech, UK), and basic fibroblast growth factor (bFGF, 20 ng/ml; PeproTech, UK). GSCs were cultured in a 37°C, 5% CO 2 incubator.
RNA Isolation and Real-time Quantitative PCR
Total RNA was extracted from normal U87 cells and U87 GSCs using the TRIzol reagent (Invitrogen, Carlsbad, USA). The amount of RNA was quantified by measuring the absorbance at A 260 and stored at 280°C until use. The TaqMan-based real-time reverse transcription-polymerase chain reaction (RT-PCR) assay was used to determine the relative expression level of miR-34a. Primers and probes for hsa-miR-34a and the RNU6B endogenous control for the TaqMan miRNA assay were purchased from Applied Biosystems. Real-time PCR was performed according to the manufacturer's instructions on an ABI 7300 HT Sequence Detection System (Applied Biosystems, CA). The relative expression level of miR-34a was normalized to the level of RUN6B and miR-34a expression levels were calculated using the 2 2DDCt method.
Immunofluoresence Staining to Detect the Expression of Stem Cell Surface Markers
The isolated CD133-positive U87 cells were cultured in serum-free neural stem cell medium for one week to allow tumor sphere formation. The spheres were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, and then incubated with mouse anti-human CD133, Nestin, and stem cell differentiation mark-Glial fibrillary acidic protein (GFAP) (Abcam, USA, 1:100) primary antibodies at 4°C overnight. Subsequently, the stained tumor spheres were incubated at 37°C with a FITC-conjugated goat anti-mouse antibody (Sigma, USA, 1:100) for 1.5 h. The nuclei of tumorsphere cells were counterstained with DAPI. The cell surface markers listed above were detected and photographed using a laser scanning confocal microscope.
Cell Transfection
2′-O-methyl (2′-O-Me) hsa-miR-34a mimics, or miR-34a scramble oligonucleotides, were chemically synthesized by Shanghai GenePharma Company (Shanghai, China). The 2′-O-Me-hsa-miR-34a mimic sequences were 5′-UGGCAGUGUCUUAGCUGGUUGU-3′ and 5′-UUACCGUCACAGAAUCGACCAA-3′. The scrambled sequences were 5′-UUCUCCGAACGUGUCACGUTT-3′ and 5′-ACGUGACACGUUCGGAGAATT-3′. Cells that were 70-80% confluent were transfected with the oligonucleotides using the Lipofectamine 2000 reagent (Invitrogen, Carlsbad, USA). Transfection was performed according to the manufacturer's instructions, and the final oligonucleotide concentration was 10 nmol/L. Transfection medium was replaced 6 h later.
Secondary Sphere Formation Assay
The primary tumorspheres were dissociated and transfected with the miR-34a mimics for 48 h. Next, 100 cells were dispensed into each well of a 96-well plate in 0.2 ml of neural stem cell medium. The secondary sphere numbers were counted and photographed seven days later.
Soft Agar Colony Assay
The primary tumorspheres were transfected with the miR-34a mimics for 48 h. Then, 2 3 10 4 cells were seeded in 0.35% agar in the middle layer. In each well of a 24-well plate, a 0.5% agar layer was plated on the bottom, and covered with a 0.35% agar layer on top. Plates were incubated in a 37°C, 5% CO 2 incubator for two weeks. Cell colonies were photographed and counted in microscopic fields at 1003 magnification. Groups consisting of more than 30 cells were considered colonies whereas groups consisting of fewer cells were considered clusters.
Cell Cycle Analysis
Cells were collected 48 h after treatment with the miR-34a mimics, washed 3 times with PBS, and then fixed with 75% ethanol at -20°C for at least 1 h. After extensive washing with PBS, the cells were resuspended in HBSS containing 50 µg/ ml RNase A (Boehringer Mannheim, Indianapolis, IN) and 50 µg/ml PI (Sigma-Aldrich), incubated for 1 h at room temperature, and then analyzed by FACScan (Becton Dickinson, San Jose, CA).
Apoptosis Assays
The Annexin V-FITC Apoptosis Detection Kit (BD Biosciences, USA) was used to analyze apoptosis 48 h post-transfection according to the manufacturer's instructions. Annexin V 2 and PI 2 cells were used as controls. Annexin V 1 and PI 2 cells were considered apoptotic, and Annexin V 1 and PI 1 cells were designated as necrotic.
Western Blotting Assays
Total protein was collected using a Total Protein Extraction Kit (KeyGen, China) and quantified using a BCA Protein Assay Kit (KeyGen, China). Twenty micrograms of protein was added for One-dimensional sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis using a Laemmli discontinuous buffer system (Bio-Rad Laboratories, USA). The electrophoresed proteins were transferred onto a polyvinylidene difluoride membrane and subjected to immunoblot analysis with primary antibodies against Bcl-2 (Santa Cruz, USA, 1:300), Bcl-xL (Santa Cruz, USA, 1:300), Bcl-w (Santa Cruz, USA, 1:400), Bax (Santa Cruz, USA, 1:500), Cyclin D1 (Santa Cruz, USA, 1:400), Ki-67 (Santa Cruz, USA, 1:500), c-myc (Santa Cruz, USA, 1:600), c-met (Santa Cruz, USA, 1:500), after exposaling, each grey value of the band was mesured by "Gelpro" software followed by the instructions and the relative expression level of each protein was normalized to the level of GAPDH (KangChen, China, 1:2000) .
Statistical Analysis
All experiments were performed three times, and statistical analyses were performed using SPSS Graduate Pack 13.0 statistical software. Descriptive statistics are presented as means 6 sd (x 6 sd). One-way ANOVAs and independent T-tests were used to analyze significant differences. P-values , 0.05 were considered statistically significant.
Results
Isolation and Characterization of GSCs from U87 Cells
U87 cells were stained with a CD133 antibody to identify U87 GSCs, and these CD133-positive cells were subsequently isolated by FACS sorting. The CD133-positive cells were then cultured in serum-free neural stem cell medium for one week, and an inverted microscope was used to observe and photograph the formation of primary tumorspheres. Primary tumorspheres were then stained with antibodies to the CD133 and Nestin stem cell markers, in addition to the GFAP differentiation marker. Immunofluorescence was used for GSC identification. The results demonstrated that GSCs can be successfully isolated from U87 cell cultures (Figure 1) .
MiR-34a is Down-Regulated in U87 GSCs
The expression level of miR-34a in U87 GSCs was determined using real-time quantitative PCR. As shown in Figure 2 , the expression level of miR-34a in normal U87 cells was approximately 3.62-fold higher than that expressed in U87 GSCs. This decreased expression of miR-34a may indicate that miR-34a plays an important role in U87 GSCs.
MiR-34a Expression is Up-Regulated by MiR-34a Mimics
FACS was used to determine the transfection efficiency of miR-34a mimics 48 h post-transfection with a FAM-conjugated oligonucleotide. As shown in Figure 3A , miR-34a mimics were successfully transfected into U87 GSCs with a transfection efficiency of 88.90%. To determine whether miR-34a mimics are functional in vitro, CD133-positive U87 cells were transfected with miR-34a mimics or miR-34a scrambles. miR-34a expression was significantly elevated by miR-34a mimics, but not miR-34a miR-34a scrambles at 48 h post-transfection (approximately 8.36-fold compared with the U87 GSC blank control) ( Figure 3B ).
MiR-34a Suppresses U87 GSC Proliferation Through Cell Cycle Arrest
Secondary sphere and soft agar colony assays were performed to determine whether miR-34a has an effect on the proliferation of U87 GSCs. We found that over-expression of miR-34a decreases sphere formation and suppresses colony formation of U87 GSCs in vitro ( Figure 4A & 4B) . Cell cycle analysis demonstrated that ectopic miR-34a expression induces cell cycle arrest in G1 phase ( Figure 4C ). Additional analyses demonstrated that miR-34a suppresses U87 GSC proliferation by modulating the expression of proliferationassociated proteins, including cyclin D1, c-myc, c-met and Ki-67 ( Figure 4D ).
MiR-34a Induces Apoptosis in U87 GSCs Through Regulating the Expression of the Bcl-2 Family of Proteins
Next, the ability of miR-34a to induce apoptosis in U87 GSCs was evaluated by co-staining with Annexin V-FITC and propidium iodide (PI). The staining demonstrated that miR-34a could significantly induce apoptosis in U87 GSCs compared with the blank and scrambled control groups ( Figure 5A ). To further explore the mechanism of miR-34a-induced apoptosis in GSCs, we analyzed changes in the Bcl-2 family of proteins. Figure 5B shows that miR-34a significantly decreases the expression of Bcl-2, Bcl-w and Bcl-xL and increases the expression of the Bax.
Discussion
Recently, GSCs have been identified in both glioma tissues and glioma cell lines, and they are thought to be the key factor in glioma recurrence and malignancy (20, 21) . This U87 glioma stem cells formed significantly more tumorspheres in serum-free neural stem cell medium. (B) The tumorspheres were stained with anti-CD133, anti-nestin, and anti-GFAP antibodies for the identification experiments. U87 GSCs were positive for the expression of the CD133 (red) and nestin (green) stem cell markers whereas they are negative for the stem cell differentiation marker, GFAP. Nuclei (Blue) were counterstained with DAPI.
into other tumor cell types to replace damaged and aging cells (22) . Additionally, GSCs express ATP-binding cassette transporters, which are able to transport chemical drugs out of the cell and protect the cell from drug-induced toxicity (23) . Moreover, GSCs can promote radio-resistance by preferential activation of the DNA damage response (21). Only limited progress in basic research and the treatment of human glioma has occurred in recent years, and this lack of improvement is thought to be at least partially due to the contribution of GSCs. Thus, GSC-targeted therapy for glioma is becoming a hot spot of research activity for the treatment of glioma.
MicroRNAs regulate gene and protein expression by binding to their target mRNA sequence in the 3' untranslated region (UTR) with an imperfect complementarity and thereby inhibit mRNA translation rather than causing its degradation. Abnormally expressed miRNAs that act as tumor oncogenes or anti-oncogenes in glioma tumorigenesis have been identified (9, 24, 25) . Later studies have also demonstrated that some miRNAs are aberrantly expressed and have functional significance in TSCs (11, 26, 27) , including GSCs. Godlewski et al. found that miR-128 could specifically block GSC self-renewal and proliferation consistent with Bmi-1 down-regulation (28). Shi et al. found that miR-125b is critical for the suppression of proliferation in human U251 glioma stem cells through modulation of the cell cycle-regulated proteins, CDK6 and CDC25A (12) .
MiR-34a acts as a tumor suppressor in many cancers (29-31) and has some functional consequences in TSCs. Ji et al. reported that restoration of miR-34a significantly inhibited the growth and invasion of pancreatic cancer tumor-initiating cells, induced apoptosis and G1 phase cell cycle arrest, and sensitized the cells to chemotherapy and radiation by directly modulating Bcl-2 and Notch1/2 expression (32). Furthermore, forced expression of miR-34a in bulk or in purified CD44(1) prostate cancer stem cells inhibited clonogenic expansion, tumor regeneration, and metastasis whereas the expression of miR-34a antagomirs in CD44(2) prostate cancer stem cells promoted tumor development and metastasis (33). Guessous et al. (19) showed that miR-34a expression was lower in p53-mutant glioma versus wild-type p53 glioma. They also demonstrated that miR-34a induces GSC differentiation and inhibits cell proliferation, G(1)/S cell cycle progression, cell survival, cell migration, and cell invasion in 0308 and 1228 GSCs through target oncogenes, including c-Met, . miR-34a is a part of the p53 network and acts as a tumor suppressor in the p53 mutant U251 glioma cell line (17). We selected U87 GSCs reasoning is based partially on the observation that existing therapeutic tools do not target GSCs. Although normal glioma cells are killed, GSCs can maintain tumor homoeostasis through their ability to self-renew and differentiate to investigate the role of miR-34a in wild-type p53 stem cells. First, we examined the relative expression level of miR-34a in CD133-positive and normal U87 cells. We found that miR-34a expression was significantly lower in U87 GSCs, which indicates that miR-34a may have an important role in U87 GSCs. Next, we identified the biological effect of miR-34a by transfecting U87 GSCs with miR-34a scrambles, or miR-34a mimics. All results suggested that forced expression of miR-34a consistently suppresses proliferation of U87 GSCs by inducing cell cycle arrest in G1 phase, and causing cell apoptosis. Additional research demonstrated that miR-34a modulates the expression of proliferation-and apoptosisassociated proteins, including cyclin D1, c-met, ki-67, c-myc, and the Bcl-2 family, some of which have previously been reported as direct target genes of miR-34a (17-19, 32, 34) .
All data indicate that one or more processes related to the self-renewal and immortalization abilities of U87 GSCs are affected by miR-34a.
In summary, our study highlights the essential role of miR-34a in regulating the stemness of U87 GSCs. Restoration of miR-34a suppresses proliferation and induces apoptosis in U87 GSCs through modulating target gene expression. Additionally, these results also suggest that using specific sense miRNA oligonucleotides, or miRNA mimics, to increase the expression of oncogene miRNAs or the use of antisense miRNA oligonucleotides, also known as miRNA antagomirs, to silence the expression of anti-oncogene miRNAs can potentially serve as stem cell-based therapeutic strategies for glioma. The efficacy of miRNA oligonucleotides have been validated in animal experiments (35); however, the function of a particular miRNA is often tissue specific and may target many mRNAs, and the target genes themselves may have different or even opposite functions in different tumors. Thus, additional studies are needed if we hope to use miRNA oligonucleotides for cancer treatment. 
